Risk of Systemic Toxicity from Topical Ophthalmic Chloramphenicol

Everitt HA , Little PS , Smith PWF. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ 2006; 333: 321–324.

Rose PW , Harnden A , Brueggemann AB. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care. Lancet 2005; 366: 37–43.

Robbie SJ , Qureshi K , Kashani S. Research into management strategies for acute infective conjunctivitis. Brit Med J 2006; 333: 446–447.

Kumar P , Clark M (eds). Clinical Medicine. 5th ed. London: Bailliere Tindall, WB Saunders, 2002. p 40.

McKusick VA. Mendelian Inheritance in Man vol 3. 12th ed. Baltimore and London: The John Hopkins University Press, 1998. 3576(no.515000).

Fernandez de Sevilla T , Alegre J , Vallespi T. Adult pure red cell aplasia following topical ocular chloramphenicol. Br J Ophthalmol 1990; 74: 640.

Shell JW. Pharmocokinetics of topically applied drugs. Surv Ophthalmol 1982; 26: 207–218.

McCurdy C. Plasma concentration of chloramphenicol and bone marrow suppression. Blood 1963; 21: 363–372.

Kapusnik-Uner JE , Saude MA , Chambers HF. Antimicrobial agents, tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In Hardman JG , Limbird LE (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York McGraw Hill, 1996. p 1132.

West JB (ed). Best and Taylor's Physiological Basis of Medical Practice. Baltimore: Williams and Wilkins, 1990. p 119.

Shearman DJC , Finlayson N , Camilleri M (eds) Diseases of the Gastrointestinal Tract and Liver 3rd ed. New York: Churchill Livingstone, 1970. p 715.

Rhoades RA , Tanner GA (eds) Medical Physiology. New York, Boston: Little Brown and Co, 1995. p426.

Chambers HF. Choramphenicol, tetracyclines, macrolides, clindamycin, & streptogramins. In Katzung BG (ed) Basic and Clinical Pharmacology. 8th ed. New York: Lange Medical Books/McGraw Hill, 2001. p 775.

Normann Ek , Bakken O , Peltola J. Treatment of acute neonatal bacterial conjunctivitis: A comparison of fucidic acid to chloramphenicol eye drops. Acta Ophthalmol Scand 2002; 80: 183–187.

Pamphlet accompanying package of drops “Optrex”. Infected eyes: eye drops: choloramphenicol. 2007.

Rosenthal RL , Blackman A. Bone marrow hypoplasia following the use of chloramphenicol eye drops. JAMA 1965; 191: 136–137.

Frauenfelder FT , Bagby GC Jr . Fatal aplastic anaemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93: 356.

Frauenfelder FT , Morgan RL , Yunis AA. Blood dyscrasia and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993; 115: 812–3.

Adler G , McElwain GE , Merli GJ. Systemic effects of eyedrops. Arch Intern Med 1982; 142: 2293–4.

Davidson SI. Systemic effects of eyedrops. Trans Ophthalmol Soc UK 1974; 94: 487–494.

Doona M , Walsh JB. Use of chloramphenicol as topical eye medication: Time to cry halt? Authors’ reply. BMJ 1995; 311: 451.

Lancaster T , Swart AM , Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. BMJ 1998; 316: 667.

Smith AG , Dovey GJ , Cartwright RA. Topical chloramphenicol and the risk of acute leukaemia in adults. Pharmacoepidemiol Drug Saf 2000; 9: 215–219.

Hall AV , Das SS , Tabaqchali S. Is it time to stop using chloramphenicol on the eye? Risk is low in short courses. BMJ 1995; 311: 450.

Doona M , Walsh JB. Use of chloramphenicol as topical eye medication: Time to cry halt? BMJ 1995; 310: 1217–8.

Buckley RJK , Kirkness CM , Kanski JJ. Is it time to stop using chloramphenicol on the eye? Safe in patients with no history of blood dyscrasia. BMJ 1995; 311: 450.

Mulla RJ , Barnes E , Rogers TR. Is it time to stop using chloramphenicol on the eye? Fears are based on only six cases. BMJ 1995; 311: 450.

Cox J , Roderick EM. General practitioners would expect to see aplasia roughly once each century. BMJ 1995; 311: 451.

Gordon-Smith EC , Marsh JCW , Geary CG. Prospective study of aplastic anaemia should give definitive answer. BMJ 1995; 31: 450.

News in Brief. BMJ 2005; 330: 1406.

Frauenfelder FW , Frauenfelder FT. Perspective. Scientific challenges in post-marketing surveillance of ocular adverse drug reactions. Am J Ophthalmol 2007; 143: 145–9.

Walker S , Diaper CJM. Bowman R et al. Lack of evidence for systemic toxicity following chloramphenicol use. Eye 1998; 12: 875–9.

Trope GE , Lawrence JR , Hind VMD. Systemic absorption of topically applied chloramphenicol eye drops. Br J Ophthalmol 1979; 63: 690–1.

Besamusca FW , Bastaensen LA. Blood dyscrasias and topically applied chloramphenicol in ophthalmology. Doc Ophthalmol 1986; 64: 87–95.

Abrams SM , Degnan TJ , Vinciguerra V. Marrow aplasia following topical application of chloramphenicol eye ointment. Arch Int Med 1980; 140: 576.

Brodsky E , Biger Y , Zeiden Z. Topical application of chloramphenicol eye ointment followed by fatal bone marrow aplasia. Isr J Med 1989; 25: 54.